- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.06. | Neola Medical AB: Neola Medical granted Patent in the U.S. for reducing optical noise in lung monitoring measurements | 138 | GlobeNewswire (Europe) | Neola Medical AB (publ) has been granted a patent in the U.S. for a technical solution that reduces noise in measurements for continuous lung monitoring. The patent protects an innovation designed to... ► Artikel lesen | |
| 02.06. | Listing of subscription rights and paid subscription shares of Neola Medical AB | 243 | GlobeNewswire | With effect from June 03, 2026, the subscription rights in Neola Medical AB will be traded on First North Growth Market. Trading will continue up until and including June 12, 2026.
... ► Artikel lesen | |
| 19.05. | Neola Medical AB: Neola Medical Q1 Report 2026 - Positive safety results from clinical study in preterm born babies strengthen the path toward market | 163 | GlobeNewswire (Europe) | During the quarter, Neola Medical completed enrollment and reported positive safety results from its first clinical pilot study in preterm born babies in Sweden. The study confirmed a favorable safety... ► Artikel lesen | |
| 21.04. | Neola Medical AB: Neola Medical Reports Positive Safety Results from First Clinical Pilot Study and Advances Towards Next Phase of Clinical Development | 132 | GlobeNewswire (Europe) | Neola Medical today announces final results from its clinical pilot study, confirming a favorable safety profile of Neola® across the studied patient population, including very low birth weight preterm... ► Artikel lesen | |
| 16.03. | Neola Medical AB: Neola Medical Completes Enrollment in Swedish Clinical Pilot Study | 302 | GlobeNewswire (Europe) | Neola Medical announces completion of patient enrollment in its clinical pilot study on preterm born babies in Sweden. All ten babies have now been included in the study, marking an important milestone... ► Artikel lesen | |
| 12.02. | Neola Medical: Strategischer Fokus auf klinische Validierung und US-Markteintritt im Q4 2025 Earnings Call | 1 | Investing.com Deutsch | ||
| 12.02. | Neola Medical AB: Neola Medical Q4 Report 2025 - Advancing IP Protection as a Core Strategic Asset across Key Markets | 152 | GlobeNewswire (Europe) | During the quarter four new patents were granted, adding in total of seven new patent grants during 2025. This marks Neola Medical's strongest year to date in terms of IP protection across all key target... ► Artikel lesen | |
| NEOLA MEDICAL Aktie jetzt für 0€ handeln | |||||
| 02.12.25 | Neola Medical AB: Neola Medical granted U.S. patent for disposable probes, strengthening future revenue model in target market | 193 | GlobeNewswire (Europe) | Neola Medical AB (publ) announces today that the company has been granted a U.S. patent protecting its disposable probes for the medical device Neola®. The advanced light and detector probes are used... ► Artikel lesen | |
| 13.11.25 | Neola Medical AB: Neola Medical granted Patent in China for reducing optical noise in lung monitoring measurements | 209 | GlobeNewswire (Europe) | Neola Medical AB (publ) has been granted its first patent in China for a technical solution that reduces noise in measurements for continuous lung monitoring. The patent protects an innovation designed... ► Artikel lesen | |
| 04.11.25 | Neola Medical AB: Revised Timeline Announced as Clinical Pilot Study Indicates Robust Safety and Need for Optimization of Neola | 167 | GlobeNewswire (Europe) | Preliminary results from Neola Medical's ongoing clinical pilot study on preterm born babies indicate a robust safety profile of the medical device Neola®.
The preliminary findings indicate variations... ► Artikel lesen | |
| 04.11.25 | Neola Medical AB: Neola Medical Q3 Report 2025 - Progressing toward completion of Swedish clinical pilot study and strengthening leadership team | 131 | GlobeNewswire (Europe) | During the quarter Neola Medical strengthened the leadership team with appointment of a Clinical Director. In addition, the company's IP portfolio was reinforced in Europe with a newly granted patent... ► Artikel lesen | |
| 16.10.25 | Neola Medical AB: Neola Medical Strengthens Global IP Portfolio with New Patents Granted in both the U.S. and China for Medical Device Neola | 198 | GlobeNewswire (Europe) | Neola Medical AB (publ) has been granted patents in both the U.S. and China for a technical method that improve the accuracy of continuous lung monitoring with the company's medical device, Neola®.... ► Artikel lesen | |
| 25.09.25 | Neola Medical AB: Neola Medical strengthens leadership team with appointment of Clinical Director | 250 | GlobeNewswire (Europe) | Neola Medical AB (publ) is pleased to announce the appointment of Eva Bondesson as Clinical Director, effective October 1, 2025. As Neola Medical advances through the clinical phase, Eva Bondesson brings... ► Artikel lesen | |
| 10.09.25 | Neola Medical AB: Neola Medical granted European patent enabling lung monitoring beyond preterm born babies | 193 | GlobeNewswire (Europe) | Neola Medical AB (publ) announces today that the company has been granted a European patent for an invention aiming to enable lung monitoring in broader patient groups. This new patent complements the... ► Artikel lesen | |
| 25.08.25 | Neola Medical AB: Neola Medical Q2 Report 2025 - First U.S. Clinical Study Site Agreement Signed, Key Step in Regulatory Path to Market Authorization | 227 | GlobeNewswire (Europe) | Neola Medical advanced its U.S. regulatory pathway in the second quarter of 2025, signing an agreement with Children's Regional Hospital at Cooper and securing IRB approval to enable the initiation... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 35,560 | +2,80 % | UBS stuft Siemens Healthineers auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Siemens Healthineers von 51 auf 38 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Mehrere Risikofaktoren belasteten... ► Artikel lesen | |
| FRESENIUS | 41,690 | -2,07 % | DAX nach Rekord tiefer: Börsen-Beben in Südkorea - Bayer, Rheinmetall, Fresenius und Kion ... | Beim deutschen Leitindex zeichnet sich am Dienstag ein schwächerer Start in den Handelstag ab. Schlechte Vorgaben aus Asien belasten den DAX. Während der Nikkei zur Stunde rund zwei Prozent verliert... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 42,940 | +2,41 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat FMC auf "Underweight" mit einem Kursziel von 37,40 Euro belassen. Aus neuesten Daten zu Nierenerkrankungen im Endstadium gehe hervor, dass immer... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 69,63 | -0,01 % | Raymond James initiates BrightSpring Health stock with outperform rating | ||
| HEARTFLOW | 26,160 | 0,00 % | Heartflow, Inc.: New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management | ||
| BILLIONTOONE | 123,25 | 0,00 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 31,560 | +3,14 % | BERNSTEIN RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Carl Zeiss Meditec mit einem Kursziel von 26,10 Euro auf "Market-Perform" belassen. Dies schrieb Analystin Susannah Ludwig am... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 20,380 | 0,00 % | Kaplan Fox & Kilsheimer LLP: Kaplan Fox Alerts Investors of Alignment Healthcare, Inc. (ALHC) to an Investigation of Potential Securities Law Violations | New York, New York--(Newsfile Corp. - July 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or... ► Artikel lesen | |
| PROGYNY | 31,990 | +0,03 % | KeyBanc raises Progyny stock price target on utilization strength | ||
| ONCOLOGY INSTITUTE | 6,250 | 0,00 % | BTIG hebt Kursziel für Oncology Institute Aktie nach Umschuldung auf 9 US-Dollar an | ||
| BETA BIONICS | 16,960 | +0,06 % | Beta Bionics, Inc.: Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 27,890 | 0,00 % | Privia Health Group, Inc. - 8-K, Current Report | ||
| GENEDX | 63,81 | -0,06 % | Piper Sandler raises GeneDx stock price target on coverage policy | ||
| LIFESTANCE HEALTH GROUP | 10,875 | -0,05 % | LifeStance Health Group, Inc. - 8-K, Current Report | ||
| GERRESHEIMER | 28,680 | +0,70 % | SUSS MicroTec: Attacke von BlackRock - Gerresheimer: Drei Fonds, zwei Richtungen | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert, unterliegt Transparenzpflichten gemäß EU-Leerverkaufsverordnung. Ab einer Netto-Leerverkaufsposition von 0,5 Prozent des ausgegebenen Aktienkapitals... ► Artikel lesen |
Das Unternehmen NEOLA MEDICAL AB kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEOLA MEDICAL AB finden Sie auf Wallstreet Online.